Table 1.
Baseline characteristics.
| Analysis Population (n = 769) | ITT Population (n = 975) | ||||
|---|---|---|---|---|---|
| No. | % | No. | % | p value | |
| Median age, years (IQR) | 61 (54–67) | 61 (54–67) | 0.76 | ||
| Median baseline CA125, IU/L (IQR) | 168 (72–458) | 168 (71–458) | 0.99 | ||
| Treatment | |||||
| CP | 399 | 52 | 509 | 52 | 0.89 |
| CPLD | 370 | 48 | 466 | 48 | |
| ECOG | |||||
| 0 | 494 | 64 | 603 | 62 | 0.82 |
| 1 | 241 | 31 | 322 | 33 | |
| 2 | 20 | 3 | 28 | 3 | |
| Histology | |||||
| Serous | 556 | 72 | 700 | 72 | 1.00 |
| Endometrioid | 56 | 7 | 73 | 7 | |
| Other | 157 | 20 | 170 | 17 | |
| FIGO | |||||
| I–II | 102 | 13 | 123 | 13 | 1.00 |
| III | 558 | 73 | 712 | 74 | |
| IV | 92 | 12 | 115 | 12 | |
| Measurable disease | |||||
| Yes | 553 | 72 | 700 | 72 | 0.96 |
| No | 216 | 28 | 275 | 28 | |
| Largest tumour size | |||||
| ≤1 cm | 573 | 75 | 717 | 74 | 0.65 |
| >1 cm | 196 | 25 | 258 | 26 | |
| PFI | |||||
| 6–12 months | 267 | 35 | 344 | 35 | 0.81 |
| >12 months | 502 | 65 | 631 | 65 | |
| No. of previous lines of therapy | |||||
| 1 line | 646 | 84 | 825 | 85 | 0.67 |
| 2 lines | 121 | 16 | 146 | 15 | |
IQR inter-quartile range, CP carboplatin/paclitaxel, CPLD carboplatin/pegylated liposomal doxorubicin, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynaecology and Obstetrics, PFI platinum free interval.